Covered recipient · General Payments record
YEKATERINA MD KARPITSKAYA
Allopathic & Osteopathic Physicians Orthopaedic Surgery
General Payments · PY2018–2024
$8,844.68
- Reported across 84 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,208.58 | 3 |
| Food and Beverage | $304.43 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Arthrex, Inc. | $1,059.70 | 14 |
| ALON MEDICAL TECHNOLOGY | $435.88 | 2 |
| Bioventus LLC | $17.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alon Medical Technology | $353.88 | 01/29/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1089020089 | CMS |
| Alon Medical Technology | $82.00 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089020087 | CMS |
| Arthrex, Inc. | $427.35 | 02/22/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1146493577 | CMS |
| Arthrex, Inc. | $427.35 | 02/23/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1146493574 | CMS |
| Arthrex, Inc. | $10.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493592 | CMS |
| Arthrex, Inc. | $10.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493596 | CMS |
| Arthrex, Inc. | $10.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493600 | CMS |
| Arthrex, Inc. | $10.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493604 | CMS |
| Arthrex, Inc. | $10.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493607 | CMS |
| Arthrex, Inc. | $45.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493615 | CMS |
| Arthrex, Inc. | $45.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493619 | CMS |
| Arthrex, Inc. | $10.00 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493581 | CMS |
| Arthrex, Inc. | $10.00 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493585 | CMS |
| Arthrex, Inc. | $10.00 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493589 | CMS |
| Arthrex, Inc. | $30.00 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493611 | CMS |
| Arthrex, Inc. | $5.00 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146493623 | CMS |
| Bioventus LLC | $17.43 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137442942 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.